We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC).
- Authors
Harrison, Michael R; Hahn, Noah M; Pili, Roberto; Oh, William K; Hammers, Hans; Sweeney, Christopher; Kim, Kyungmann; Perlman, Scott; Arnott, Jamie; Sidor, Carolyn; Wilding, George; Liu, Glenn
- Abstract
2ME2 (Panzem®) is a non-estrogenic derivative of estradiol with antiproliferative and antiangiogenic activity. Preclinical data support antitumor activity in prostate cancer. This trial evaluated the efficacy of 2ME2 NCD in patients with taxane-refractory, metastatic CRPC.
- Publication
Investigational new drugs, 2011, Vol 29, Issue 6, p1465
- ISSN
1573-0646
- Publication type
Journal Article
- DOI
10.1007/s10637-010-9455-x